Actelion plans buyback amid takeover buzz

With its slumping share price revived by persistent rumors of a possible takeover, Actelion announced plans to buy back up to $827 million shares in the next three years. The Swiss biotech insists that it also wants to remain independent, but that hasn't blunted investors' enthusiasm for a deal. Story

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.